A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia

Trial Profile

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms OPAL-HK
  • Sponsors Relypsa
  • Most Recent Events

    • 21 Jul 2017 According to a Relypsa media release, the European Commission (EC) approved the Marketing Authorization Application (MAA) for Veltassa (patiromer) for the treatment of hyperkalemia.
    • 19 May 2017 According to a Vifor media release, based on the results from this trial, Phase 2 AMETHYST-DN trial, and from one phase 1 (CTP-700241167) trial, The Committee For Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorisation for patiromer for the treatment of hyperkalemia.
    • 03 Nov 2016 According to a Relypsa media release, pooled analysis of this and other clinical trial (AMETHYST-DN)will be presented at the American Society of Nephrology's (ASN) Kidney Week 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top